小剂量地西他滨联合阿糖胞苷治疗骨髓增生异常综合征临床观察  

Clinical observation of low-dose decitabine combined with cytarabine in the treatment of myelodysplastic syndromes

作　　者：黄达永[1] 付丽[1] 魏娜[1] 王晶石[1] 沈晶[1] 吴林[1] 王旖旎[1] 崔华[1] 王昭[1] 

机构地区：[1]首都医科大学附属北京友谊医院血液科,100050

出　　处：《白血病．淋巴瘤》2016年第7期406-408,共3页Journal of Leukemia & Lymphoma

摘　　要：目的：探讨小剂量地西他滨联合阿糖胞苷治疗骨髓增生异常综合征（MDS）的临床疗效和安全性。方法收集2012年1月至2015年1月接受小剂量地西他滨联合阿糖胞苷方案治疗的15例MDS 患者临床资料，评价其疗效和不良反应。结果15例患者中完全缓解4例，部分缓解5例，稳定、进展和无效6例，总有效率为60.0%（9／15）。总感染率为40.0%（6／15），其中肺部感染率为26.7%（4／15），Ⅲ～Ⅳ度骨髓抑制率为73.3%（11／15）。患者经积极抗感染、刺激造血及输血等支持治疗后感染得到控制。15例患者均无严重肝损害，未出现化疗相关死亡。结论小剂量地西他滨单药联合阿糖胞苷方案治疗 MDS 有一定疗效，可延缓疾病进展，患者能耐受化疗不良反应，无化疗相关死亡。Objective To explore the clinical efficacy and safety of low-dose decitabine combined with cytarabine for myelodysplastic syndromes （MDS）. Methods Clinical data of 15 patients with MDS who took the therapeutic regimen with decitabine combined with cytarabine were collected from January 2012 to January 2015. The clinical efficacy and adverse effects were assessed. Results Among the 15 patients, 4 cases were complete remission （CR）, 5 cases were partial remission （PR） and 6 cases were stable disease （SD） and progressive disease （PD）. The total effective rate was 60.0 % （9/15）. Grade Ⅲ-Ⅳ bone marrow depression occurred in 11 cases with incidence rate of 73.3 % （11/15）, and the total incidence rate of infection was 40.0 % （6/15）, including lung infection of 26.7 % （4/15）. All the infections were controlled after active supportive treatment and anti-infection therapy. No patient died of chemotherapy. Conclusions Low-dose decitabine combined with cytarabine can effectively treat MDS and delay the progress of disease. The patients can tolerate the adverse effects in chemotherapy with a low mortality rate.

关 键 词：骨髓增生异常综合征 地西他滨 阿糖胞苷 

分 类 号：R551.3[医药卫生—血液循环系统疾病]